{"slideshow_credits": null, "snippet": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "abstract": "Justice Department says Johnson & Johnson has agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that it improperly promoted antipsychotic drug Risperdal to older adults, children and people with developmental disabilities.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": ""}, "web_url": "http://www.nytimes.com/2013/11/05/business/johnson-johnson-to-settle-risperdal-improper-marketing-case.html", "lead_paragraph": "Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.", "headline": {"main": "J.&J. to Pay $2.2 Billion in Risperdal Settlement", "print_headline": "J.&J. to Pay $2.2 Billion In Risperdal Settlement"}, "_id": "5277d8b738f0d8702adc8258", "word_count": "1113", "multimedia": [{"height": 126, "url": "images/2013/11/05/business/Drug2/Drug2-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2013/11/05/business/Drug2/Drug2-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 783, "url": "images/2013/11/05/business/Drug1/Drug1-articleLarge.jpg", "legacy": {"xlarge": "images/2013/11/05/business/Drug1/Drug1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "783"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "legacy": {"thumbnail": "images/2013/11/05/business/Drug2/Drug2-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2013-11-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Mental Health and Disorders", "name": "subject", "is_major": "Y", "rank": "5"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Johnson & Johnson", "name": "organizations", "is_major": "Y", "rank": "1"}, {"value": "Fines (Penalties)", "name": "subject", "is_major": "N", "rank": "2"}, {"value": "Advertising and Marketing", "name": "subject", "is_major": "Y", "rank": "4"}], "blog": [], "subsection_name": null, "type_of_material": "News"}